H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line ...

and Evkeeza is showing a path to zodasiran adding $200 million+ to Arrowhead’s topline at peak and more than $100 million to the bottom line due to the significant operating leverage through the ...